Brought to you by 
Sapheon brings in $8.6mm so far through its planned $18.5mm Series B venture round; closes at $19.8mm
30 Sep 2020
Executive Summary
Vascular disease device developer Sapheon Inc. has raised $8.6mm through the first closing of its Series B venture round. It issued 4.8mm shares to 33 investors and hopes to bring in $18.5mm when the financing is completed. Aaron Berez, MD, former CEO of Chestnut Medical Technologies, will take a seat on the company’s board. Sapheon is developing the VenaSeal system to close the saphenous vein in cases of venous reflux disease.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com